Klotho Neurosciences (NASDAQ:KLTO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Klotho Neurosciences (NASDAQ:KLTO) to a hold rating in a research note published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Klotho Neurosciences Price Performance

Shares of NASDAQ:KLTO opened at $0.53 on Friday. The business’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.46. Klotho Neurosciences has a 1 year low of $0.11 and a 1 year high of $3.91. The firm has a market capitalization of $39.09 million, a price-to-earnings ratio of -1.66 and a beta of 10.27.

Institutional Trading of Klotho Neurosciences

Large investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in Klotho Neurosciences in the 2nd quarter worth approximately $26,000. XTX Topco Ltd increased its holdings in shares of Klotho Neurosciences by 101.2% in the fourth quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock valued at $46,000 after purchasing an additional 80,768 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Klotho Neurosciences during the fourth quarter worth approximately $126,000. Geode Capital Management LLC lifted its position in Klotho Neurosciences by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after buying an additional 167,905 shares in the last quarter. Finally, Brummer Multi Strategy AB acquired a new position in Klotho Neurosciences during the fourth quarter worth $175,000. Hedge funds and other institutional investors own 20.07% of the company’s stock.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.